Progressive ototoxicity of neomycin monitored using derived brainstem response audiometry.
Progressive hearing loss following the systemic administration of neomycin was investigated using derived brainstem response audiometry. Cats were given three to five times the maximum recommended clinical dose of neomycin over a period of 10 days. Their hearing was monitored prior to and during the administration of the drug, and periodically following its completion. The results of this study showed that the induced hearing loss generally proceeded from high to low frequencies as an advancing lesion, with regions apical to the lesion functioning normally. Although considerable variability in response to the drug existed among animals, the evoked responses from both ears of each animal showed close bilateral symmetry during the deafening process. Furthermore, the present results highlight the long-term ongoing ototoxicity associated with neomycin, and the importance of monitoring high frequencies for initial signs of an aminoglycoside induced hearing loss.
D000818:Animals; D001300:Audiometry, Evoked Response; D001309:Auditory Threshold / Q000187:drug effects*; D001933:Brain Stem / Q000187:drug effects*; D002415:Cats; D003051:Cochlea / Q000187:drug effects; D005072:Evoked Potentials, Auditory / Q000187:drug effects*; D009355:Neomycin / Q000633:toxicity*; D010898:Pitch Perception / Q000187:drug effects*
D009355:Neomycin